Company to be Renamed NOMAD Power Solutions • First-to-Market with the Mobile, Utility-Grade 1 MW BESS • Addressing a Multi-Hundred-Billion-Dollar...
Milestone demonstrates how internet communities can drive real change: funding prevention, supporting wellness, and proving that collective action mattersYucca Valley,...
- JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - - Selective...
Echo IQ's AI platform to be evaluated in collaboration with Mayo Clinic for assessing cardiac risk in patients receiving cancer...
-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of...
— Growing body of ORLADEYO® clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare utilization...
COPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its...
— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile — —The ESLIM-02 study underscores sovleplenib’s potential to...
Cover Image Eliaz Therapeutics Launches Reg CF Raise to Advance First Device Targeting Sepsis Santa Rosa, CA, USA, June 11,...
Cover Image Hiding in Plain Sight: New Survey Exposes Awareness Gap Around the Second Most Common Type of Breast Cancer...
NEW HAVEN, Conn., June 11, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that it will...
The Emerging Techbio Company Appoints Dr. John Mumm as CSO Alongside Head of Platform Dr. Yambazi Banda to Decode the...
BATON ROUGE, LA / ACCESS Newswire / June 11, 2026 / Two of Louisiana's premier emergency medicine providers, Professional Emergency...
Company earns five Golds for its interactive patient education tools, health literacy content, and evidence-based behavioral health appsATLANTA, June 11,...
- Following the pre-specified interim safety report and overwhelming demand from clinicians to treat patients as quickly as possible, Alpha...
Kennewick, WA, June 11, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy™...
Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with...
Pooled Phase 1/2 data show 80% complete remission rate in pediatric R/R T-ALL/LBL patients Global TENACITY-01 study reports 86% overall...
Management Believes the Company is Entering a Transformative Stage with a Novel, First-In-Class Cancer Therapy for Treatment & Prevention of...
PET-CT imaging, Rather than CT Alone, Presented a Meaningful Reduction in Tumor Metabolic Activity After Treatment, Suggesting that PET May...